共 50 条
- [31] Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6-to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy StudyAMERICAN JOURNAL OF KIDNEY DISEASES, 2016, 67 (06) : 912 - 924Provenzano, RobertBesarab, AnatoleWright, StevenDua, SohanZeig, StevenNguyen, PeterPoole, LonaSaikali, Khalil G.Saha, GopalHemmerich, StefanSzczech, LyndaYu, K. H. PeonyNeff, Thomas B.
- [32] New combination therapies with subcutaneous epcoritamab in first-line therapy and in relapsed non-Hodgkin lymphoma. A phase 1b/2 multicenter, open-label study to assess safety, tolerability, and efficacyONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 196 - 196Duell, J.Skarbnik, A. P.Avivi, IBrody, J.Yoon, D. H.Elliott, B. M.Siddani, S. R.Bai, Y.Parikh, A.Seliem, M. M.Dinh, M. H.Sehn, L. H.
- [33] Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-3-Year Safety and Efficacy Follow-upBLOOD, 2015, 126 (23)Dimopoulos, Meletios A.Lonial, SagarWhite, DarrellMoreau, PhilippePalumbo, AntonioSan Miguel, JesusShpilberg, OferAnderson, Kenneth C.Grosicki, SebastianSpicka, IvanWalter-Croneck, AdamMagen-Nativ, HilaMateos, Maria-VictoriaBelch, AndrewReece, DonnaBeksac, MeralBleickhardt, EricPoulart, ValerieKatz, JessicaSinghal, Anil K.Richardson, Paul G.
- [34] Biomarker Correlates of Response to Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma from CARTITUDE-1, a Phase 1b/2 Open- Label Study, at the ∼3 Year Follow-upBLOOD, 2023, 142de Oca, Rocio MontesGu, JunchenZhao, HaoZelinsky, KathyWu, DiannaDavis, CucPatel, JaymalaFoulk, BradBoominathan, RengasamyLau, OnsaySmirnov, DenisLin, YiJagannath, SundarCohen, Adam D.Haddish-Berhane, NahorXu, JeanMadduri, DeepuStevens, An-SofieJackson, Carolyn ChangSchecter, Jordan M.Banerjee, ArnobGeng, DongZhu, JieqingXu, SifanZudaire, Enrique
- [35] 2-YEAR FOLLOW-UP OF RADIUM-223 RE-TREATMENT IN AN INTERNATIONAL, OPEN-LABEL, PHASE 1/2 STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER AND BONE METASTASESJOURNAL OF UROLOGY, 2018, 199 (04): : E695 - E696Mariados, NeilSartor, OliverHeinrich, DanielMendez Vidal, Maria JoseKeizman, DanielKarlsson, Camilla ThellenbergPeer, AvivitProcopio, GiuseppeFrank, Stephen J.Pulkkanen, KaleviRosenbaum, EliSeveri, StefanoPerez, Jose Manuel TrigoTrandafir, LuciaWagner, VolkerLi, RuiNordquist, Luke T.
- [36] Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple MyelomaBLOOD, 2012, 120 (21)Lust, John A.Usmani, Saad Z.Hamadani, MehdiBarranco, CharlesLacy, Martha Q.Dispenzieri, AngelaGertz, Morie A.Dingli, DavidRussell, StephenBuadi, Francis K.Zeldenrust, Steven R.Hayman, Suzanne R.Rajkumar, S. VincentKumar, Shaji K.Thompson, JohnTaylor, Catherine A.Dondero, Richard
- [37] Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastasesPROSTATE, 2019, 79 (14): : 1683 - 1691Sartor, OliverHeinrich, DanielMariados, NeilMendez Vidal, Maria JoseKeizman, DanielKarlsson, Camilla ThellenbergPeer, AvivitProcopio, GiuseppeFrank, Stephen J.Pulkkanen, KaleviRosenbaum, EliSeveri, StefanoTrigo, JoseTrandafir, LuciaWagner, VolkerLi, RuiNordquist, Luke T.
- [38] A PHASE 1A/1B, MULTI-CENTER, OPEN-LABEL DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF THE PLEIOTROPIC PATHWAY MODIFIER CC-122 ADMINISTERED ORALLY TO PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM) AND OTHER BRAIN TUMORSNEURO-ONCOLOGY, 2016, 18 : 24 - 24Simonelli, MatteoSepulveda, JuanBrandes, AlbaSoria, Jean-CharlesEdenfield, JohnMoreno, VictorPerez-Larraya, Jaime GallegoBritten, CarolynCloughesy, Timothy F.Matinez Garcia, MariaBalana, CarmeHagner, PatrickLi, YanWei, XinGandhi, AnitaPourdehnad, MichaelLopez Martin, Jose AntonioSantoro, ArmandoShih, Kent
- [39] A Phase 1/2a, multicenter, open-label, non-randomized first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1303 in patients with advanced/metastatic solid tumorsCANCER RESEARCH, 2023, 83 (08)Hamilton, ErikaZhang, JianLiu, LimingGao, JieShi, RongLiu, ShengxueWei, GuQiu, YangMoore, Kathleen
- [40] A Phase 3b, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia VeraBLOOD, 2023, 142Mascarenhas, JohnTashi, TsewangEl Chaer, FirasPriego, VictorZagrijtschuk, OlehQin, AlbertJessup, JewellZimmerman, CraigUrbanski, RayMasarova, Lucia